IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma
Monday, November 29, 2021 1 min read
Key Takeaway: IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma
Full Press Release Details
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma.